Recruiting Heart Attack Studies in New Hyde Park
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE...
Avexitide for Treatment of Post-Bariatric Hypoglycemia
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess...
About Heart Attack Clinical Trials in New Hyde Park
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 2 heart attack clinical trials recruiting participants in New Hyde Park, NY. These studies are seeking a combined 175 participants. Research is being sponsored by AstraZeneca, Amylyx Pharmaceuticals Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in New Hyde Park — FAQ
Are there heart attack clinical trials in New Hyde Park?
Yes, there are 2 heart attack clinical trials currently recruiting in New Hyde Park, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New Hyde Park?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Hyde Park research site will contact you about next steps.
Are clinical trials in New Hyde Park free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Hyde Park studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 2 active trials in New Hyde Park are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov